An Open Label, Prospective, Randomized, Comparative, Multiple Arm Clinical Study to Evaluate the Immunomodulatory Efficacy of Nichi Glucan in Comparison with Conventional Therapeutic Regimen in Adult Subjects with Covid 19 caused by SARS-CoV2(B-CoV)

ichiIn Biosciences Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Adult subjects between 18 and 65 years (both ages and sexes(inclusive) who are confirmed to be positive for SARS-CoV2 by way of RT-PCR in a laboratory approved by MoH-FW and the State Government.
•2. Patients with co-morbidities can be included.
•3. Patients who are found to be Covid19 positive requiring hospitalization. (Symptomatic or asymptomatic)
•4. Patients and LAR who is willing to give informed consent for participation, able to comprehend and understand the responsibilities during treatment period.
•5. Patients who are willing not to participate in any other clinical trial during participation in the current trial.

•1. Patients who have previously been infected with SARS-CoV2 (symptomatic or
•Asymptomatic ) and recovered.
•2. Patients who are known to be HIV, HBV, HCV positive.
•3. Patients who have clinically abnormal renal or hepatic function values that are 3x times normal upper limit or in the opinion of the Investigator would impact the objectives of the study.
•4. Patients with complete cancer remission less than 3 years prior to the date of screening.
•5. Patients who have undergone major surgical procedure 4 weeks prior to randomization.
•6. Patients who are on anti-depressants, anti-psychotics.
•7. Patients with known history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases; expect those that are considered etiology of said indication
•8. Females who are pregnant or nursing or planning to become pregnant during the study period.

发起方

ichiIn Biosciences Pvt Ltd